These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 18449489)
21. Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients. Millán O; Urtasun N; Brunet M Transplant Rev (Orlando); 2009 Apr; 23(2):120-8. PubMed ID: 19298943 [TBL] [Abstract][Full Text] [Related]
22. Biomarkers for cardiovascular disease: challenges and future directions. May A; Wang TJ Trends Mol Med; 2008 Jun; 14(6):261-7. PubMed ID: 18487087 [TBL] [Abstract][Full Text] [Related]
23. The future of biomarkers in the management of patients with acute coronary syndromes. O'Donoghue M; Morrow DA Curr Opin Cardiol; 2008 Jul; 23(4):309-14. PubMed ID: 18520713 [TBL] [Abstract][Full Text] [Related]
24. Proteomics: new technologies and clinical applications. Latterich M; Abramovitz M; Leyland-Jones B Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654 [TBL] [Abstract][Full Text] [Related]
25. From conservation genetics to conservation genomics. Primmer CR Ann N Y Acad Sci; 2009 Apr; 1162():357-68. PubMed ID: 19432656 [TBL] [Abstract][Full Text] [Related]
26. Biomarkers in geriatric psychiatry: searching for the holy grail? Blumberger DM; Daskalakis ZJ; Mulsant BH Curr Opin Psychiatry; 2008 Nov; 21(6):533-9. PubMed ID: 18852558 [TBL] [Abstract][Full Text] [Related]
27. Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials. Sinchaikul S; Hongsachart P; Sriyam S; Tantipaiboonwong P; Phutrakul S; Chen ST Chang Gung Med J; 2008; 31(5):417-30. PubMed ID: 19097588 [TBL] [Abstract][Full Text] [Related]
28. Biological biomarkers in psoriatic disease. A review. de Vlam K; Gottlieb AB; Fitzgerald O J Rheumatol; 2008 Jul; 35(7):1443-8. PubMed ID: 18609742 [TBL] [Abstract][Full Text] [Related]
29. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW; Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852 [TBL] [Abstract][Full Text] [Related]
31. Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Day M; Balci F; Wan HI; Fox GB; Rutkowski JL; Feuerstein G Curr Opin Investig Drugs; 2008 Jul; 9(7):696-706. PubMed ID: 18600575 [TBL] [Abstract][Full Text] [Related]
32. Quantitative proteomics for drug toxicity. Gao Y; Holland RD; Yu LR Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682 [TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics and therapeutic strategies for dementia. Cacabelos R Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004 [TBL] [Abstract][Full Text] [Related]
34. Integrative genomics--a basic and essential tool for the development of molecular medicine. Ostrowski J Acta Pol Pharm; 2008; 65(6):621-4. PubMed ID: 19172842 [TBL] [Abstract][Full Text] [Related]
35. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089 [TBL] [Abstract][Full Text] [Related]